Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is worrying, and the application of heparin in COVID‐19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ning, Bai, Huan, Chen, Xing, Gong, Jiale, Li, Dengju, Sun, Ziyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906401/
https://www.ncbi.nlm.nih.gov/pubmed/32220112
http://dx.doi.org/10.1111/jth.14817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906401/
https://www.ncbi.nlm.nih.gov/pubmed/32220112
http://dx.doi.org/10.1111/jth.14817

Ejemplares similares